Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,600

Document Document Title
WO/2019/099336A1
Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or...  
WO/2019/095116A1
The invention relates to the technical field of polyurethane polymeric materials, and particularly to induced light-emitting polyurethane and a preparation method of the induced light-emitting polyurethane. The polyurethane takes a hydro...  
WO/2019/096911A1
The present invention relates to macrocyclic indole derivatives of general formula (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said...  
WO/2019/086141A1
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...  
WO/2019/090076A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2019/085978A1
The present invention relates to heteroaryl amide compounds, a preparation method therefor, pharmaceutical compositions thereof and applications thereof, and specifically, relates to a type of compounds having broad-spectrum tumor resist...  
WO/2019/089580A1
The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.  
WO/2019/089422A1
Compounds of Formula I as IRAK4 inhibitors are disclosed. The pharmaceutical compositions comprising compounds of formula I, methods of synthesis of these compounds, methods of treatment for diseases associated with IRAK-4 such as inflam...  
WO/2019/082808A1
This pest control agent contains, as an active ingredient, a compound represented by formula (I) or a salt thereof, and at least one selected from the group consisting of the compound and a salt thereof. In formula (I), Ar represents a p...  
WO/2019/080941A1
This invention relates to certain novel tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors, their synthesis and their use for treating diseases. More particularly, this invention is directed to fused heterocyclic deri...  
WO/2019/076343A1
Disclosed are a PD-1/PD-L1 small-molecule inhibitor and a preparation method therefor and use thereof. In particular, disclosed are a compound which has a structure as shown in formula L, a stereoisomer or a tautomer thereof, or a pharma...  
WO/2019/074007A1
A polymerizable liquid crystal compound which is represented by general formula (1). (In general formula (1), the symbols are as defined in the description.)  
WO/2019/072906A1
The invention relates to compounds of formula (I): wherein the variables are defined in the specification. The invention also relates to a pesticidal mixture comprising a compound of formula (I), and another agrochemically active ingredi...  
WO/2019/068679A1
The present invention relates to compounds of the formula (1 ) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2019/070093A1
The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or ...  
WO/2019/063288A1
The invention relates to an organic compound, in particular for the use in optoelectronic devices. According to the invention, the organic compound has - a first chemical moiety with a structure of formula (I), and - two second chemical ...  
WO/2019/057660A1
The present invention relates to heteroaryl compounds of formula (Ia) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer,an isotopic form, a N-oxide or a S-oxide thereof. The present invention furt...  
WO/2019/035863A8
Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.  
WO/2019/035865A8
Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.  
WO/2019/035864A8
Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.  
WO/2019/052535A1
The present invention provides a compound for inhibiting and degrading a CDK. Specifically, the present invention provides a compound represented by formula I, definitions of radical groups being described in the specification. The compo...  
WO/2019/053617A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Form┬ÁLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...  
WO/2019/043407A1
There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists o...  
WO/2019/046150A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stere...  
WO/2019/043139A1
A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.  
WO/2019/037861A1
Compounds of formula (I) wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2019/038717A1
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1,R2, Rx, XI, n, nl, and q are as defined herein, methods of making ...  
WO/2019/037678A1
Provided are a pyrazolo[3,4-d]pyrimidin-3-one derivative as shown in formula (I) or (I') and/or a pharmaceutically acceptable salt thereof, and a composition containing the compound as shown in formula (I) or (I') and/or the pharmaceutic...  
WO/2019/040573A1
The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a ne...  
WO/2019/040550A1
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treatinga neop...  
WO/2019/035863A1
Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): Formula (I) wherein R', R2, L', and L2 are as defined herein.  
WO/2019/035865A1
Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.  
WO/2019/034725A1
The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.  
WO/2019/035864A1
Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.  
WO/2019/034096A1
Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1....  
WO/2019/027765A1
Disclosed are new small molecules having a substituted pyrimidine or substituted fused pyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising t...  
WO/2019/025099A1
The invention relates to thiazolopyridine derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mamma...  
WO/2019/020987A1
The present invention relates to compounds which are of use in the field of agriculture as herbicides. The compounds in question are of formula II and comprise a spirofused tricycle core: wherein R4 and R5 together with the carbon atom t...  
WO/2019/016324A1
The invention relates to an amphiphilic organic molecule for the self-assembly of active layers in electronic components, said molecule having at least one donor-acceptor system and chemical groups, wherein the donor-acceptor system incl...  
WO/2019/018718A1
Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease...  
WO/2019/011767A1
The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.  
WO/2019/014300A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2019/011770A1
The present invention relates to 2-oxo-1,3-oxazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.  
WO/2019/011323A1
Disclosed are an endocyclic thiamidinoamide-arylamide compound and a pharmaceutical composition comprising the compound described above, and the use of the compound or pharmaceutical composition in the treatment of hepatitis B. In partic...  
WO/2019/004114A1
Provided is a production method for efficiently synthesizing a compound (1-2) which is an important intermediate in production of edoxaban. The method comprises dripping a compound (1-1) into a solution A that is obtained by causing a re...  
WO/2018/234342A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/234805A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2018/233648A1
The present invention provides a novel isothiazolo[4,3-d]pyrimidine-5,7-diamine derivative. In particular, the present invention provides a compound shown in formula (I) and a pharmaceutically acceptable salt thereof.  
WO/2018/229141A1
The present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with a drug against a disease involving gram-positive bacteria.  
WO/2018/230595A1
The present invention addresses the problem of providing a composition having a high refractive index and being capable of forming a film having exceptional appearance characteristics. The present invention also addresses the problem of ...  

Matches 1 - 50 out of 9,600